Related references
Note: Only part of the references are listed.Ameliorative effect of atractylenolide III in the mast cell proliferation induced by TSLP
Myoung-schook Yoou et al.
FOOD AND CHEMICAL TOXICOLOGY (2017)
Anti-inflammatory activity of atractylenolide III through inhibition of nuclear factor-κB and mitogen-activated protein kinase pathways in mouse macrophages
Guang-Quan Ji et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2016)
Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients
Jayakumar Hascitha et al.
CLINICAL BIOCHEMISTRY (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
MicroRNA-146a regulates ICOS-ICOSL signalling to limit accumulation of T follicular helper cells and germinal centres
Alvin Pratama et al.
NATURE COMMUNICATIONS (2015)
Early carcinogenesis involves tne establishment of immune privilege via intrinsic anc extrinsic regulation of indoleamine 2,3-dioxygenase-1: translational implications in cancer immunotherapy
Alisha Holtzhausen et al.
FRONTIERS IN IMMUNOLOGY (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3
Cinzia Fionda et al.
JOURNAL OF IMMUNOLOGY (2013)
Kynurenines in the CNS: recent advances and new questions
Laszlo Vecsei et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2013)
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
Theodore S. Johnson et al.
IMMUNOLOGICAL INVESTIGATIONS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier et al.
CLINICAL CANCER RESEARCH (2011)
PD-L1 expression on tolerogenic APCs is controlled by STAT-3
Sabine J. Woelfle et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Interferon-γ-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells
Birgit Juergens et al.
BLOOD (2009)
Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro
Changhe Wang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
Lisa K. Jasperson et al.
BLOOD (2008)
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
Alexander J. Muller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
David H. Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Atractylenolide I and atractylenolide III inhibit lipopolysaccharide-induced TNF-α and NO production in macrophages
Cui-qin Li et al.
PHYTOTHERAPY RESEARCH (2007)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
Share Paper
